Abstract:IMPORTANCE Recent advances in newborn screening (NBS) have improved the diagnosis of inborn errors of metabolism (IEMs); however, many potentially treatable IEMs are not included on NBS panels, nor are they covered in standard, first-line biochemical testing. OBJECTIVE To examine the utility of untargeted metabolomics as a primary screening tool for IEMs by comparing the diagnostic rate of clinical metabolomics with the recommended traditional metabolic screening approach. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study compares data from 4464 clinical samples received from 1483 unrelated families referred for trio testing of plasma amino acids, plasma acylcarnitine profiling, and urine organic acids (June 2014 to October 2018) and 2000 consecutive plasma samples from 1807 unrelated families (July 2014 to February 2019) received for clinical metabolomic screening at a College of American Pathologists and Clinical Laboratory Improvement Amendments-certified biochemical genetics laboratory. Data analysis was performed from September 2019 to August 2020. EXPOSURES Metabolic and molecular tests performed at a genetic testing reference laboratory in the US and available clinical information for each patient were assessed to determine diagnostic rate. MAIN OUTCOMES AND MEASURES The diagnostic rate of traditional metabolic screening compared with clinical metabolomic profiling was assessed in the context of expanded NBS. RESULTS Of 1483 cases screened by the traditional approach, 912 patients (61.5%) were male and 1465 (98.8%) were pediatric (mean [SD] age, 4.1 [6.0] years; range, 0-65 years). A total of 19 families were identified with IEMs, resulting in a 1.3% diagnostic rate. A total of 14 IEMs were detected, including 3 conditions not included in the Recommended Uniform Screening Panel for NBS. Of the 1807 unrelated families undergoing plasma metabolomic profiling, 1059 patients (58.6%) were male, and 1665 (92.1%) were pediatric (mean [SD] age, 8.1 [10.4] years; range, 0-80 years). Screening identified 128 unique cases with IEMs, giving an overall diagnostic rate of 7.1%. In total, 70 different metabolic conditions were identified, including 49 conditions not presently included on the Recommended Uniform Screening Panel for NBS. CONCLUSIONS AND RELEVANCE These findings suggest that untargeted metabolomics provided a 6-fold higher diagnostic yield compared with the conventional screening approach and identified a broader spectrum of IEMs. Notably, with the expansion of NBS programs, traditional metabolic testing approaches identify few disorders beyond those covered on the NBS. These data support the capability of clinical untargeted metabolomics in screening for IEMs and suggest that broader screening approaches should be considered in the initial evaluation formetabolic disorders.

Study on Urinary Profile of Inborn Errors of Metabolism by 18-Crown-6 Modified Capillary Electrophoresis with Laser-Induced Fluorescence Detection.

[Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up].

The screening of inborn errors of metabolism in sick Chinese infants by tandem mass spectrometry and gas chromatography/mass spectrometry.

Selective Screening of Inborn Errors of Metabolism by Urease Pretreatment-Gas Ch Romatography-Mass Spectrometry:Pilot Study of 327 Patients at High Risk

A targeted metabolomic procedure for amino acid analysis in different biological specimens by ultra-high-performance liquid chromatography-tandem mass spectrometry

Metabolomic Profiling of Human Urine as a Screen for Multiple Inborn Errors of Metabolism.

Targeted ultra performance liquid chromatography tandem mass spectrometry procedures for the diagnosis of inborn errors of metabolism: validation through ERNDIM external quality assessment schemes

Etiological Spectrum and Clinical Characteristics of Neonates with High Risk of Inborn Errors of Metabolism: A Five-year Retrospective Analysis

B-201 Development of a Quantitative Gas Chromatography Tandem Mass Spectrometry Method for Metabolic Profiling of Urine Organic Acids

A novel, high throughput, and low-cost method for the detection of 40 amines relevant to inborn errors of metabolism, in under 60 minutes, using reverse phase high performance liquid chromatography

Screening for Inborn Errors of Metabolism in High-Risk Children: a 3-Year Pilot Study in Zhejiang Province, China

A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism

Study on Urinary Metabolic Profile of Phenylketonuria by Micellar Electrokinetic Capillary Chromatography with Dual Electrochemical Detection—potential Clinical Application in Fast Diagnosis of Phenylketonuria

Newborn Screening for Inborn Errors of Metabolism by Next-Generation Sequencing Combined with Tandem Mass Spectrometry

Screening of 1.17 million newborns for inborn errors of metabolism using tandem mass spectrometry in Shanghai, China: A 19-year report

Untargeted Metabolomic Analysis for the Clinical Screening of Inborn Errors of Metabolism

Rapid Determination of Amino Acids in Neonatal Blood Samples Based on Derivatization with Isobutyl Chloroformate Followed by Solid‐phase Microextraction and Gas Chromatography/mass Spectrometry

Early Noninvasive Diagnosis of Phenylketonuria of Infants by Capillary Electrophoresis with Amperometric Detection

[A Pilot Study of Selective Screening for High Risk Children with Inborn Error of Metabolism Using Tandem Mass Spectrometry in China].

Comparison of Untargeted Metabolomic Profiling vs Traditional Metabolic Screening to Identify Inborn Errors of Metabolism

Selective Screening for Inborn Errors of Metabolism and Secondary Methylmalonic Aciduria in Pregnancy at High Risk District of Neural Tube Defects: a Human Metabolome Study by GC-MS in China.